Candel Therapeutics, Inc.CADLEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Candel Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing oncolytic immunotherapies for cancer treatment. Its product pipeline covers solid tumors and hematological malignancies, serving global oncology markets and addressing unmet medical needs for patients with limited treatment options.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| CVI Investments, Inc. | 5.60% | 2.4M | — | 2024-12-17 |
Insider Transactions
Net 90d: +$3.00M · buys $3.00M / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-23 | Manning Paul B | Director | Buy (open market) | 550.5K | $5.45 | $3.00M |
1–1 of 1